Plain-English translation of NCT03495427 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a specialized imaging scan called F-DCFPyL PSMA PET to see how well it can detect prostate cancer that has come back or spread to other parts of the body. The scan uses a small amount of radioactive material to help doctors find cancer cells more clearly. Researchers want to understand if this newer imaging technique works better than standard scans for patients whose genetic tests show they have high-risk prostate cancer.
Standard imaging tests don't always reliably detect early signs that prostate cancer has spread, especially in high-risk patients. This trial exists to see whether this new imaging approach could help doctors catch cancer recurrence earlier, which could lead to better treatment outcomes.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive a specialized imaging scan once per year for 4 years. Each scan involves receiving a small injection of radioactive material through an IV, then lying still in a scanner while it takes pictures to look for any signs of cancer spread. The visits are outpatient procedures, meaning you go home the same day. Your doctor will use these scans to monitor your prostate cancer and help guide your future care.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States